Literature DB >> 23115655

Salivary immunoglobulin classes in Nigerian smokers with periodontitis.

Olatunde A Olayanju1, Sheu K Rahamon, Ijeboime O Joseph, Olatunbosun G Arinola.   

Abstract

AIM: To determine the levels of salivary immunoglobulin classes in Nigerian smokers and non-smokers with periodontitis.
METHODS: Sixty-nine individuals were recruited into this study after obtaining informed consent. They were subdivided into three groups that consisted of 20 (aged 46 ± 11 years) cigarette smokers with periodontitis (S+P); 24 (40 ± 12 years) smokers without periodontitis (S-P); and 25 (53 ± 11 years) non-smokers with periodontitis (NS+P). An oral and maxillofacial surgeon used radiographs for periodontal probing for the diagnosis of periodontitis. The smokers included subjects who smoked at least six cigarettes per day and all the periodontitis patients were newly diagnosed. About 5 mL of unstimulated saliva was expectorated by each subject into plain sample bottles. Salivary immunoglobulin levels were estimated using enzyme linked immunosorbent assay. Student's t test was used to determine significant differences between the means. Values of P < 0.05 were regarded as significant.
RESULTS: No significant differences were observed in the mean salivary levels of the immunoglobulin classes (IgG, IgA, IgM and IgE) when S+P was compared with S-P. Mean salivary levels of IgA (520.0 ± 155.1 ng/mL vs 670.0 ± 110 ng/mL, P = 0.000) and IgM (644.5 ± 160.0 ng/mL vs 791.4 ± 43.7 ng/mL, P = 0.000) were significantly lower in the S+P compared with NS+P group. Salivary IgA (570.4 ± 145.6 ng/mL vs 670.0 ± 110 ng/mL, P = 0.008) and IgM (703.1 ± 169.3 ng/mL vs 791.4 ± 43.7 ng/mL, P = 0.012) levels were significantly lower in the S-P compared with NS+P group. Only one (5%) periodontal patient had detectable levels of salivary IgE (0.20 IU/mL). Similarly, only one smoker (4.17%) had detectable levels of salivary IgE (0.04 IU/mL) and two non-smokers (9.52%) had detectable levels of IgE (0.24 IU/mL).
CONCLUSION: Our study suggests that reduced salivary IgA and IgM levels in smokers with periodontitis could enhance increased susceptibility to periodontitis.

Entities:  

Keywords:  Cigarette smoke; Immunoglobulin; Periodontitis; Saliva; Smokers

Year:  2012        PMID: 23115655      PMCID: PMC3484323          DOI: 10.4331/wjbc.v3.i10.180

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  15 in total

Review 1.  Analysis of saliva for periodontal diagnosis--a review.

Authors:  E Kaufman; I B Lamster
Journal:  J Clin Periodontol       Date:  2000-07       Impact factor: 8.728

Review 2.  Systemic humoral immune responses in periodontal disease.

Authors:  J L Ebersole
Journal:  Crit Rev Oral Biol Med       Date:  1990

3.  Ante-dependence modeling in a longitudinal study of periodontal disease: the effect of age, gender, and smoking status.

Authors:  M J Faddy; M P Cullinan; J E Palmer; B Westerman; G J Seymour
Journal:  J Periodontol       Date:  2000-03       Impact factor: 6.993

4.  Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey.

Authors:  S L Tomar; S Asma
Journal:  J Periodontol       Date:  2000-05       Impact factor: 6.993

5.  Association between passive smoking and salivary markers related to periodontitis.

Authors:  Nobuko Nishida; Yumiko Yamamoto; Muneo Tanaka; Kazuhiko Maeda; Kosuke Kataoka; Kunio Nakayama; Kanehisa Morimoto; Satoshi Shizukuishi
Journal:  J Clin Periodontol       Date:  2006-08-03       Impact factor: 8.728

6.  Effects of tobacco products on the attachment and growth of periodontal ligament fibroblasts.

Authors:  J A James; N M Sayers; D B Drucker; P S Hull
Journal:  J Periodontol       Date:  1999-05       Impact factor: 6.993

Review 7.  Mechanisms of action of environmental factors--tobacco smoking.

Authors:  Richard M Palmer; Ron F Wilson; Adam S Hasan; David A Scott
Journal:  J Clin Periodontol       Date:  2005       Impact factor: 8.728

8.  The influence of smoking and race on adult periodontitis and serum IgG2 levels.

Authors:  S M Quinn; J B Zhang; J C Gunsolley; H A Schenkein; J G Tew
Journal:  J Periodontol       Date:  1998-02       Impact factor: 6.993

9.  Initial serum antibody titer to Porphyromonas gingivalis influences development of antibody avidity and success of therapy for chronic periodontitis.

Authors:  J Mooney; E Adonogianaki; M P Riggio; K Takahashi; A Haerian; D F Kinane
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 10.  Cigarette smoking and the periodontal patient.

Authors:  Georgia K Johnson; Margaret Hill
Journal:  J Periodontol       Date:  2004-02       Impact factor: 6.993

View more
  5 in total

1.  sIgA, peroxidase and collagenase in saliva of smokers aggressive periodontal patients.

Authors:  Myriam A Koss; Cecilia E Castro; Agustina M Gramajo; María E López
Journal:  J Oral Biol Craniofac Res       Date:  2016-09-03

2.  Altered antigenic profiling and infectivity of Porphyromonas gingivalis in smokers and non-smokers with periodontitis.

Authors:  Iris Zeller; Justin A Hutcherson; Richard J Lamont; Donald R Demuth; Pinar Gumus; Nejat Nizam; Nurcan Buduneli; David A Scott
Journal:  J Periodontol       Date:  2013-10-23       Impact factor: 6.993

3.  Comparative Evaluation of Salivary Biomarker Levels in e-Cigarette Smokers and Conventional Smokers.

Authors:  Abhishek Verma; Kumar Anand; Manish Bhargava; Amulya Kolluri; Madhuresh Kumar; Devendra H Palve
Journal:  J Pharm Bioallied Sci       Date:  2021-11-10

4.  Secretory immunity with special reference to the oral cavity.

Authors:  Per Brandtzaeg
Journal:  J Oral Microbiol       Date:  2013-03-11       Impact factor: 5.474

5.  Evaluation of Microcirculation, Cytokine Profile, and Local Antioxidant Protection Indices in Periodontal Health, and Stage II, Stage III Periodontitis.

Authors:  Artem Eldzharov; Dzerassa Kabaloeva; Dmitry Nemeryuk; Aida Goncharenko; Adelina Gatsalova; Elena Ivanova; Igor Kostritskiy; Florence Carrouel; Denis Bourgeois
Journal:  J Clin Med       Date:  2021-03-18       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.